Biological products

Abstract

There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.

What is claimed is: 
     
         1 . An antibody molecule that binds human CD22 comprising a heavy chain and a light chain, wherein each chain comprises three complementarity determining regions (CDRs), wherein CDR-H1 comprises the amino acid sequence of SEQ ID NO:1; CDR-H3 comprises the amino acid sequence of SEQ ID NO:3; CDR-L1 comprises the amino acid sequence of SEQ ID NO:4; CDR-L2 comprises the amino acid sequence of SEQ ID NO:5; and CDR-L3 comprises the amino acid sequence of SEQ ID NO:6. 
     
     
         2 . The antibody molecule of  claim 1 , which is a CDR-grafted antibody molecule. 
     
     
         3 . The antibody molecule of  claim 2 , wherein the variable domain comprises human acceptor framework regions and non-human donor CDRs. 
     
     
         4 . A composition comprising the antibody molecule of  claim 1 . 
     
     
         5 . The composition according to  claim 4 , comprising a pharmaceutically acceptable excipient, diluent, or carrier. 
     
     
         6 . The composition according to  claim 4 , additionally comprising anti-T cell, anti-IFNγ, anti-LPS antibodies, or a non-antibody ingredient.